KROS
Keros Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.32
+1.89%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.94
- Revenue estimate
- $14.8M
Latest reported
- Last report date
- Aug 3, 2026
- EPS actual
- -$1.45
- EPS estimate
- -$1.34
- Revenue actual
- —
- Revenue estimate
- $807.1K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -7.9%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $21
- PT range
- $18 – $23
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026